Oral contraceptive formulation and socio-cognitive performance: a short communication [0.03%]
口服避孕药的配方与社会认知表现：简短通讯
Minhal Mussawar,Sneha Chenji,Christine Bueno et al.
Minhal Mussawar et al.
Background: Oral contraceptives (OC) offer a range of ethinyl estradiol (EE) doses and progestin types, with evidence indicating marked differences in cognitive and emotional abilities in OC users. However, it remains unc...
Clinical and biochemical factors associated with hyperammonemia in inpatients with mental disorders treated with valproic acid: a cross-sectional analysis [0.03%]
与接受丙戊酸钠治疗的精神疾病住院患者高血氨症相关的临床和生化因素：横断面分析
Ilaria Riboldi,Daniele Cavaleri,Marco Morreale et al.
Ilaria Riboldi et al.
Background: Valproic acid (VPA)-induced hyperammonemia is a common condition whose clinical presentations can range from asymptomatic cases to severe hyperammonemic encephalopathy. This can happen at any stage of treatmen...
Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms [0.03%]
酌情减量和停用阿片类药物的指导原则，以最大限度地减少戒断症状的影响
Mark Abie Horowitz,Adele Framer,John Strang et al.
Mark Abie Horowitz et al.
Formal guidelines recommend that opioids should be stopped when risks outweigh benefits. These guidelines generally recommend gradual dose tapering at a rate tolerable to the patient. However, there is considerable variation regarding the p...
Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners' and physicians' perspectives [0.03%]
澳大利亚老年护理机构中医生和全科医师对治疗痴呆患者行为和心理症状的 psychotropic 药物与非药物方法的看法比较研究
Hunduma D Ayeno,Mustafa Atee,Gizat M Kassie et al.
Hunduma D Ayeno et al.
Background: Psychotropic medications are often inappropriately prescribed for behavioural and psychological symptoms of dementia (BPSD), posing significant risks such as falls, stroke and death. Although non-pharmacologic...
Real-world examination of the rates of long-acting injectable attrition in a cohort of early psychosis patients after discharge from an early intervention service for psychosis [0.03%]
早期精神病患者出院后一段时间内长效注射药物脱落率的现实世界研究
Candice E Crocker,Thomas Hastings,Marc-Andre Roy et al.
Candice E Crocker et al.
Background: Patients treated in early intervention for psychosis programs have better treatment outcomes and higher rates of long-acting injection (LAI) antipsychotic medication utilization (20%-50%) versus treatment as u...
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review [0.03%]
血清素致幻剂治疗反应的生物学标志物：系统性回顾
Stanley Wong,Brett D M Jones,Mathura T Thiyagarajah et al.
Stanley Wong et al.
Background: Results from contemporary clinical trials of serotonergic psychedelic therapies have led to an increasing focus on their potential clinical use across mental disorders. However, studies examining mechanisms of...
Treating job-related stress with psychedelic group therapy: a case series on group ketamine-assisted psychotherapy for healthcare workers and first responders [0.03%]
针对医护人员和一线救援人员的群体氯胺酮联合心理治疗：系列案例研究
Luke Flynn,Martin Krsak,Mary Rondeau et al.
Luke Flynn et al.
Background: Job-related stress and its extreme form, burnout, continue to affect almost half of all frontline healthcare workers and first responders. Current treatments are inadequate. ...
Impact of CYP1A, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and NFIB genotypes on clozapine serum concentration in smokers and nonsmokers [0.03%]
吸烟和非吸烟者中CYP1A、CYP2C19、CYP2D6、CYP3A4、CYP3A5和NFIB基因多态性对氯氮平血药浓度的影响
Hasan Çağın Lenk,Line Skute Bråten,Ole A Andreassen et al.
Hasan Çağın Lenk et al.
Background: Clozapine is the most effective drug for schizophrenia and is the only drug indicated for use in patients with treatment resistance. The therapeutic range of clozapine is narrow with extensive interindividual ...
Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial [0.03%]
裸盖菇素结合心理治疗支持对难治性抑郁的临床研究——一项试点试验
Sally Meikle,Olivia Carter,Paul Liknaitzky et al.
Sally Meikle et al.
Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. ...
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design [0.03%]
作为一种复杂干预措施的迷幻辅助疗法及其对临床试验设计的影响
S D Muthumaraswamy,M J Baggott,E E Schenberg et al.
S D Muthumaraswamy et al.
Psychedelic-assisted therapy (PAT) has typically been evaluated using conventional randomised controlled trials (RCTs), which assess treatment efficacy under highly controlled conditions. However, PAT constitutes a complex intervention, int...